Aligos Therapeutics Inc
ALGS
查看详细走势图
7.320USD
+0.830+12.79%
收盘 02/06, 16:00（美东）报价延迟15分钟
45.04M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+12.79%
5天
-9.29%
1月
-16.44%
6月
-8.96%
今年开始到现在
-21.46%
1年
-73.38%
查看详细走势图
TradingKey Aligos Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Aligos Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业中等水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名92/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价68.20。中期看，股价处于平稳状态。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aligos Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Aligos Therapeutics Inc亮点
亮点风险
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
业绩增长期
公司处于发展阶段，最新年度总收入3.94M美元
利润高增长
公司净利润处于行业前列，最新年度总收入3.94M美元
估值合理
公司最新PE估值-0.54，处于3年历史合理位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值55.02K
分析师目标
根据
5
位分析师
买入
评级
68.200
目标均价
+950.85%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Aligos Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aligos Therapeutics Inc简介
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
公司代码ALGS
公司Aligos Therapeutics Inc
CEOBlatt (Lawrence M)
网址https://www.aligos.com/
相关品种
